











International multicentre propensity score-matched analysis comparing robotic versus laparoscopic right posterior sectionectomy

Adrian K. H. Chiow¹, David Fuks², Gi-Hong Choi³, Nicholas Syn ⁴, Iswanto Sucandy⁵, Marco V. Marino ⁶, Mikel Prieto⁷, Charing C. Chong ⁸, Jae Hoon Lee⁹, Mikhail Efanov ¹⁰, T. Peter Kingham¹¹, Sung Hoon Choi¹², Robert P. Sutcliffe¹³, Roberto I. Troisi ¹⁴, Johann Pratschke¹⁵, Tan-To Cheung ¹⁶, Xiaoying Wang¹⁷, Rong Liu¹⁸, Mathieu D'Hondt¹⁹, Chung-Yip Chan²⁰, Chung Ngai Tang²¹, Ho-Seong Han ²² and Brian K. P. Goh ^{20,*} International Robotic and Laparoscopic Liver Resection Study Group collaborators

¹Hepatopancreatobiliary Unit, Department of Surgery, Changi General Hospital, Singapore

²Department of Digestive, Oncologic and Metabolic Surgery, Institute Mutualiste Montsouris, Université Paris Descartes, Paris, France

³Division of Hepatopancreatobiliary Surgery, Department of Surgery, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

⁴Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and Yong Loo Lin School of Medicine, National University of Singapore, Singapore

⁵AdventHealth Tampa, Digestive Health Institute, Tampa, Florida, USA

⁶General Surgery Department, Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy and Oncologic Surgery Department, P. Giaccone University Hospital, Palermo, Italy

⁷Hepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Bilbao, Spain

⁸Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Hong Kong SAR, China

⁹Department of Surgery, Division of Hepato-Biliary and Pancreatic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

¹⁰Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Scientific Center, Moscow, Russia

¹¹Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA

¹²Department of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea

¹³Department of Hepatopancreatobiliary and Liver Transplant Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

¹⁴Department of Clinical Medicine and Surgery, Division of HBP, Minimally Invasive and Robotic Surgery, Federico II University Hospital Naples, Naples, Italy

¹⁵Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin, and Berlin Institute of Health, Berlin, Germany

¹⁶Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China

¹⁷Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China

¹⁸Faculty of Hepatopancreatobiliary Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China

¹⁹Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, Kortrijk, Belgium

²⁰Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital and Duke-National University Singapore Medical School, Singapore

²¹Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China

²²Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Korea

*Correspondence to: Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Level 5, 20 College Road, Academia, Singapore 169856 (e-mail: bsgkp@hotmail.com)

Members of the International Robotic and Laparoscopic Liver Resection Study Group collaborators are co-authors of this study and are listed under the heading Collaborators.

Abstract

Background: Minimally invasive right posterior sectionectomy (RPS) is a technically challenging procedure. This study was designed to determine outcomes following robotic RPS (R-RPS) and laparoscopic RPS (L-RPS).

Methods: An international multicentre retrospective analysis of patients undergoing R-RPS versus those who had purely L-RPS at 21 centres from 2010 to 2019 was performed. Patient demographics, perioperative parameters, and postoperative outcomes were analysed retrospectively from a central database. Propensity score matching (PSM) was performed, with analysis of 1:2 and 1:1 matched cohorts.

Results: Three-hundred and forty patients, including 96 who underwent R-RPS and 244 who had L-RPS, met the study criteria and were included. The median operating time was 295 minutes and there were 25 (7.4 per cent) open conversions. Ninety-seven (28.5 per cent) patients had cirrhosis and 56 (16.5 per cent) patients required blood transfusion. Overall postoperative morbidity rate was 22.1 per cent and major morbidity rate was 6.8 per cent. The median postoperative stay was 6 days. After 1:1 matching of 88 R-RPS and L-RPS patients, median (i.q.r.) blood loss (200 (100–400) versus 450 (200–900) ml, respectively; $P < 0.001$), major blood loss (> 500 ml; $P = 0.001$), need for intraoperative blood transfusion (10.2 versus 23.9 per cent, respectively; $P = 0.014$), and open conversion rate (2.3

versus 11.4 per cent, respectively; $P = 0.016$) were lower in the R-RPS group. Similar results were found in the 1:2 matched groups (66 R-RPS versus 132 L-RPS patients).

Conclusion: R-RPS and L-RPS can be performed in expert centres with good outcomes in well selected patients. R-RPS was associated with reduced blood loss and lower open conversion rates than L-RPS.

Introduction

Minimally invasive hepatectomy (MIH) is increasingly adopted and becoming standard of care in many high-volume specialist hepatopancreatobiliary (HPB) centres around the world¹⁻³. The increased adoption is, in part, due to rapid and widespread dissemination of standardized surgical techniques, development of improved technology for visualization of the operative field, equipment advancement, and increasing evidence of short- and long-term benefits of MIH compared with open surgery. These benefits include shorter hospital stay, fewer wound complications, faster return to work, and lower perioperative morbidity without compromising oncological outcomes⁴⁻⁷. Several major consensus conferences over the years have continued to define the role of MIH for surgeons worldwide, moving from guidelines for patient selection, training, and evaluations for safety and feasibility to recent discussions on precision anatomical resections⁸⁻¹².

While adoption of laparoscopic hepatectomy in general has been widespread, use of minimally invasive techniques for major hepatectomy or difficult resections has still been mainly confined to more experienced centres¹³⁻¹⁵. Amongst the difficult resections include lesions in the posterior superior segments of the liver or anatomical resections involving these segments such as formal bisegmentectomy of segment 6/7 or right posterior sectionectomy (RPS)¹⁶. These procedures performed laparoscopically would be rated with a minimum score of 6 (intermediate) and above (expert), according to the Iwate criteria¹⁷. Similarly, RPS is graded as a procedure with high difficulty, based on the Institut Mutualiste Montsouris (IMM) scoring system¹⁸. Technical challenges encountered during RPS include a long horizontal cutting plane with a wide area of transection, difficulty in isolating the posterior pedicle, dissection to expose the right hepatic vein

(RHV), and identifying the root of the RHV – all of which carry a risk of catastrophic bleeding, as well as oncological compromise with poor surgical technique in inexperienced hands. Hence, not surprisingly, reports of laparoscopic RPS (L-RPS) in the current literature have remained limited to studies with small sample sizes¹⁹⁻²².

Robotic hepatectomy (RH) shows potential improvement over traditional laparoscopy due to the presence of integrated three-dimensional high definition (HD) immersive visualization with indocyanine green (ICG) Firefly, improved scalable dexterity of surgical instruments, stable-console surgeon-controlled camera with 10× magnification, and integrated multiscreen inputs via TilePro™²³. However, barriers such as high cost, limited instrumentation, lack of an ultrasonic aspirator, possible need for a bedside specialist surgeon, and limited access continue to impede its wider adoption. Furthermore, despite its theoretical advantages, the actual advantages of RH over conventional laparoscopic hepatectomy remain debatable^{24,25}. To date, studies comparing laparoscopic hepatectomy versus RH have remained limited to small retrospective studies^{26,27}.

Given limited evidence on outcomes of MIH for RPS, this large multicentre study was conducted. The primary objective was to analyse the outcomes of robotic RPS (R-RPS) versus laparoscopic posterior sectionectomies (L-RPS) performed in 21 HPB centres specialized in MIH. To our knowledge, this is the largest study to date on MIH for RPS, and the only study comparing the outcomes of R-RPS versus L-RPS.

Methods

This was an international multicentre retrospective analysis of patients undergoing either L-RPS or R-RPS at 21 HPB centres from



Fig. 1 World map of 21 centres of the International Robotic and Laparoscopic Liver Resection Study Group

2010 to 2019 (Fig. 1). All participating institutions were given their respective approvals according to their local centre's requirements. This study was approved by the Singapore General Hospital Institution Review Board and the requirement for patient consent was waived. Anonymized data were collected in the individual centres, and were collated and analysed centrally at the Singapore General Hospital.

In this study, only patients who underwent purely laparoscopic or robot-assisted laparoscopic surgery were included. Patients who had laparoscopic-assisted (hybrid) and hand-assisted laparoscopic resections were excluded. Similarly, those undergoing donor hepatectomy for transplant and hepatectomy with bilioenteric anastomoses were also excluded.

Definitions

RPS was defined, according to the 2000 Brisbane classification, as resection of segments 6 and 7²⁸. The diameter of the largest lesion was used in cases of multiple tumours. Postoperative complications were classified according to the Clavien–Dindo classification and recorded for up to 30 days or during the same hospitalization²⁹. Difficulty of resections was rated according to the Iwate score¹⁷.

Statistical analysis

Propensity score matching (PSM) was performed to minimize confounding and selection bias^{30,31}. Before propensity score estimation, missing baseline covariates were addressed using multiple imputations (M = 50) by chained equations, with the following specifications: ordinal logistic regression for ordinal factor variables (for example, ASA classification status), five k-nearest neighbours for continuous variables (for example, tumour size), and augmented logistic regression for binary variables (for example,

sex). Propensity scores were calculated from mixed-effects logistic models, taking into account age, sex, ASA status, previous abdominal or liver surgery, pathology, cirrhosis, Child–Pugh class, presence of portal hypertension, median tumour size, multifocality, concomitant surgeries excluding cholecystectomy, and Iwate difficulty grade. A random-effects term was used to denote participating institutions to better account for between-centre variation. We evaluated discriminatory power and calibration of the propensity score model using the methods of Lemeshow and Hosmer and c-index³². The final propensity score model exhibited an area under the receiver operating curve of 0.8162 (bias-corrected 95 per cent c.i. 0.8786 to 0.9263; Fig. S1) and good calibration (Fig. S2).

To ensure the robustness of conclusion, two separate sets of comparative analyses within 1:2 and 1:1 propensity score-matched cohorts were performed. Matches between the robotic and laparoscopic groups were identified using greedy matching with a caliper of 0.25 s.d. of the linear predictor (that is, logit of propensity score). After PSM, both groups were well balanced for all variables, as shown in Table 1 and Figs S3–S5.

In the unmatched cohort, comparisons of patient characteristics and perioperative outcomes between patients who underwent R-RPS and those who had L-RPS were performed using Mann–Whitney U test and Pearson's χ^2 test for continuous and categorical variables, respectively. Comparisons in the 1:2 and 1:1 matched cohorts considered the paired nature of the data; hence, paired analyses such as the mixed-effects quantile, conditional logistic, and mixed-effects multinomial or ordinal regression models were used for continuous, binary, and multivalued categorical variables, respectively. Statistical analyses were done using Stata version 16.0 (StataCorp LLC, College Station, TX, USA), and $P < 0.05$ were considered to indicate nominal statistical significance.

Table 1 Comparison between baseline clinicopathological characteristics of R-RPS versus L-RPS

	Total n = 340	Unmatched cohort		P
		R-RPS n = 96	L-RPS n = 244	
Median age (i.q.r.), years	61 (52–69)	60 (51–69)	61 (52–70)	0.533
Male sex, n (%)	214/339 (63.1%)	64/96 (66.7%)	150/243 (61.7%)	0.396
ASA score, n (%)				<0.001
I	52/338 (15.4%)	12/96 (12.5%)	40/242 (16.5%)	
II	196/338 (58.0%)	43/96 (44.8%)	153/242 (63.2%)	
III	88/338 (26.0%)	40/96 (41.7%)	48/242 (19.8%)	
IV	2/338 (0.6%)	1/06 (1.0%)	1/242 (0.4%)	
Previous abdominal surgery, n (%)	115/340 (33.8%)	33/96 (34.4%)	82/244 (33.6%)	0.893
Previous liver surgery, n (%)	15/340 (4.4%)	4/96 (4.2%)	11/244 (4.5%)	0.890
Malignant pathology, n (%)	301/340 (88.5%)	89/96 (92.7%)	212/244 (86.9%)	0.129
Pathology type, n (%)				0.122
Hepatocellular carcinoma	179/340 (52.6%)	59/96 (61.5%)	120/244 (49.2%)	
Colorectal metastases	89/340 (26.2%)	21/96 (21.9%)	68/244 (27.9%)	
Other	72/340 (21.2%)	16/96 (16.7%)	56/244 (22.9%)	
Cirrhosis, n (%)	97/340 (28.5%)	35/96 (36.5%)	62/244 (25.4%)	0.042
Child–Pugh score, n (%)				0.104
No cirrhosis	243/340 (71.5%)	61/96 (63.5%)	182/244 (74.6%)	
A	93/340 (27.3%)	33/96 (34.4%)	60/244 (24.6%)	
B	4/340 (1.2%)	2/96 (2.1%)	2/244 (0.8%)	
Portal hypertension, n (%)	12/340 (3.5%)	2/96 (2.1%)	10/244 (4.1%)	0.365
Median tumour size, mm (i.q.r.)	36 (27–54)	35 (30–50)	37 (25–54)	0.777
Multiple tumours, n (%)	73/340 (21.5%)	16/96 (16.7%)	57/244 (23.4%)	0.176
Multiple resections, n (%)	25/340 (7.4%)	5/96 (5.2%)	20/244 (8.2%)	0.342
Concomitant operation non-cholecystectomy, n (%)	30/340 (8.8%)	5/96 (5.2%)	25/244 (10.2%)	0.140
Iwate score, n (%)				0.927
Intermediate	19/340 (5.6%)	6/96 (6.3%)	13/244 (5.3%)	
High	81/340 (23.8%)	22/96 (22.9%)	59/244 (24.2%)	
Expert	240 (70.6%)	68/96 (70.8%)	172/244 (70.5%)	

Bold represents statistically significant values.

Results

Three-hundred and forty patients met the study criteria, of whom 96 underwent R-RPS and 244 underwent L-RPS. The patients' clinicopathological features and perioperative outcomes are summarized in Tables 1 and 2. The median operating time was 295 minutes, and there were 25 (7.4 per cent) open conversions. Ninety-seven (28.5 per cent) patients had cirrhosis and 56 (16.5 per cent) patients required blood transfusion. The overall

postoperative morbidity rate was 22.1 per cent and the major morbidity rate was 6.8 per cent. The median postoperative stay was 6 days.

Comparison between R-RPS and L-RPS in entire unmatched cohort

Before matching, the R-RPS group had a significantly greater proportion of patients with higher ASA score and cirrhosis (Table 1).

Table 2 Comparison between perioperative outcomes of R-RPS versus L-RPS

	Total n = 340	Entire unmatched cohort		P
		R-RPS n = 96	L-RPS n = 244	
Median operating time (i.q.r.), min	295 (220–390)	271 (199–382)	311 (240–390)	0.019
Median blood loss (i.q.r.), ml	325 (150–700)	200 (100–500)	400 (200–800)	<0.001
Blood loss (categories), ml				<0.001
< 500 ml	193/318 (60.7%)	71/95 (74.7%)	122/223 (54.7%)	
≥ 500 ml	125/318 (39.3%)	24/95 (25.3%)	101/223 (45.3%)	
Intraoperative blood transfusion, n (%)	56/340 (16.5%)	11/96 (11.5%)	45/244 (18.4%)	0.118
Pringle manoeuvre applied, n (%)	209/339 (61.7%)	60/96 (62.5%)	149/243 (61.3%)	0.840
Median Pringle duration when applied (i.q.r.), min	45 (29–63)	40 (26–60)	45 (30–67)	0.171
Open conversion, n (%)	25/340 (7.4%)	2/96 (2.1%)	23/244 (9.4%)	0.020
Median postoperative stay, days (i.q.r.)	6 (5–8)	6 (5–8)	6 (5–8)	0.839
30-day readmission, n (%)	11/340 (3.2%)	4/96 (4.2%)	7/244 (2.9%)	0.543
Postoperative morbidity, n (%)	75/340 (22.1%)	23/96 (24.0%)	52/244 (21.3%)	0.596
Major morbidity (Clavien–Dindo grade > II), n (%)	23/340 (6.8%)	2/96 (2.1%)	21/244 (8.6%)	0.031
Reoperation, n (%)	2/340 (0.6%)	0/96 (0.0%)	2/244 (0.8%)	0.374
30-day mortality, n (%)	0/340 (0.0%)	0/96 (0.0%)	0/244 (0.0%)	n.e.
In-hospital mortality, n (%)	3/340 (0.9%)	0/96 (0.0%)	3/244 (1.2%)	0.275
90-day mortality, n (%)	5/340 (1.5%)	1/96 (1.0%)	4/244 (1.6%)	0.680
Close/involved margins (≤ 1 mm) for malignancies, n (%)	52/301 (12.4%)	11/89 (12.4%)	41/212 (19.3%)	0.144

n.e., not evaluable. Bold represents statistically significant values.

Table 3 Comparison between baseline clinicopathological characteristics of R-RPS versus L-RPS after propensity score matching

	1 : 2 propensity-matched cohort			1 : 1 propensity-matched cohort		
	R-RPS n = 66	L-RPS n = 132	P ^a	R-RPS n = 88	L-RPS n = 88	P ^a
Median age (i.q.r.), years	60 (51–70)	60 (52–69)	0.771	60 (51–69)	61 (54–69)	0.410
Male sex, n (%)	43/66 (65.2%)	87/131 (66.4%)	0.829	59/88 (67.0%)	64/88 (72.7%)	0.413
ASA score, n (%)			0.676			0.870
I	9/66 (13.6%)	19/130 (14.6%)		10/88 (11.4%)	9/87 (10.3%)	
II	36/66 (54.5%)	380/130 (61.5%)		42/88 (47.7%)	47/87 (54.0%)	
III	20/66 (30.3%)	30/130 (23.1%)		35/88 (39.8%)	30/87 (34.5%)	
IV	1/66 (1.5%)	1/130 (0.8%)		1/88 (1.1%)	1/87 (1.2%)	
Previous abdominal surgery, n (%)	20/66 (30.3%)	43/132 (32.6%)	0.744	27/88 (30.7%)	29/88 (33.0%)	0.724
Previous liver surgery, n (%)	1/66 (1.5%)	4/132 (3.0%)	0.525	2/88 (2.3%)	2/88 (2.3%)	1.000
Malignant pathology, n (%)	60/66 (90.9%)	121/132 (91.7%)	0.860	81/88 (92.0%)	83/88 (94.3%)	0.566
Pathology type, n (%)			0.871			0.914
HCC	36/66 (54.5%)	77/132 (58.3%)		52/88 (59.1%)	54/88 (61.4%)	
CRM	17/66 (25.8%)	32/132 (24.2%)		21/88 (23.9%)	21/88 (23.9%)	
Other	13/66 (19.7%)	23/132 (17.4%)		15/88 (17.0%)	13/88 (14.8%)	
Cirrhosis, n (%)	18/66 (27.3%)	45/132 (34.1%)	0.329	29/88 (33.0%)	32/88 (36.4%)	0.640
Child–Pugh score, n (%)			0.518			0.561
No cirrhosis	48/66 (72.7%)	87/132 (65.9%)		59/88 (67.0%)	56/88 (63.6%)	
A	18/66 (27.3%)	44/132 (33.3%)		29/88 (33.0%)	31/88 (35.2%)	
B	0/66 (0.0%)	1/132 (0.8%)		0/88 (0.0%)	1/88 (1.1%)	
Portal hypertension, n (%)	1/66 (1.5%)	2/132 (1.5%)	1.000	1/88 (1.1%)	2/88 (2.3%)	0.571
Median tumour size, mm (i.q.r.)	35 (28–50)	39 (29–54)	0.558	35 (30–50)	40 (30–52)	0.453
Multiple tumours, n (%)	15/66 (22.7%)	24/132 (18.2%)	0.481	16/88 (18.2%)	17/88 (19.3%)	0.853
Multiple resections, n (%)	5/66 (7.6%)	6/132 (4.6%)	0.405	5/88 (5.7%)	4/88 (4.5%)	0.739
Concomitant operation non-cholecystectomy, n (%)	4/66 (6.1%)	9/132 (6.8%)	0.831	5/88 (5.7%)	5/88 (5.7%)	1.000
Iwate score, n (%)			0.971			0.500
Intermediate	5/66 (7.6%)	10/132 (7.6%)		5/88 (5.7%)	2/88 (2.3%)	
High	14/66 (21.2%)	30/132 (22.7%)		21/88 (23.9%)	23/88 (26.1%)	
Expert	47/66 (71.2%)	92/132 (69.7%)		62/88 (70.4%)	63/88 (71.6%)	

^aP-values were obtained from conditional logistic regression or mixed-effects quantile regression for binary and continuous variables, respectively. The respective marginal models were used when convergence could not be achieved.

Table 4 Comparison between perioperative outcomes of R-RPS versus L-RPS after propensity score matching

	1 : 2 propensity-matched cohort			1 : 1 propensity-matched cohort		
	R-RPS n = 66	L-RPS n = 132	P ^a	R-RPS n = 88	L-RPS n = 88	P ^a
Median operating time (i.q.r.), min	272 (217–397)	303 (240–390)	0.172	272 (196–397)	310 (243–405)	0.132
Median blood loss (i.q.r.), ml	200 (100–400)	450 (200–800)	< 0.001	200 (100–400)	450 (200–900)	< 0.001
Blood loss (categories), ml			< 0.001			0.001
< 500 ml	51/66 (77.3%)	63/124 (50.8%)		67/88 (76.1%)	44/86 (51.2%)	
≥ 500 ml	15/66 (22.7%)	61/124 (49.2%)		21/88 (23.9%)	42/86 (48.8%)	
Intraoperative blood transfusion, n (%)	6/66 (9.1%)	29/132 (22.0%)	0.026	9/88 (10.2%)	21/88 (23.9%)	0.014
Pringle manoeuvre applied, n (%)	39/66 (59.1%)	84/131 (64.1%)	0.489	55/88 (62.5%)	56/88 (63.6%)	0.882
Median Pringle duration when applied (i.q.r.) min	36 (25–54)	45 (30–70)	0.278	39 (26–60)	45 (34–75)	0.084
Open conversion, n (%)	2/66 (3.0%)	13/132 (9.8%)	0.001	2/88 (2.3%)	10/88 (11.4%)	0.016
Median postoperative stay, days (i.q.r.)	6 (4–8)	6 (5–8)	0.925	6 (5–8)	6 (5–9)	0.845
30-day readmission, n (%)	3/66 (4.5%)	3/132 (2.3%)	0.400	3/88 (3.4%)	3/88 (3.4%)	1.000
Postoperative morbidity, n (%)	16/66 (24.2%)	27/132 (20.5%)	0.512	22/88 (25.0%)	18/88 (20.5%)	0.451
Major morbidity (Clavien–Dindo grade > II), n (%)	1/66 (1.5%)	9/132 (6.8%)	0.113	2/88 (2.3%)	7/88 (8.0%)	0.118
Reoperation, n (%)	0/66 (0.0%)	1/132 (0.8%)	0.478	0/88 (0.0%)	0/88 (0.0%)	n.e.
30-day mortality, n (%)	0/66 (0.0%)	0/132 (0.0%)	n.e.	0/88 (0.0%)	0/88 (0.0%)	n.e.
In-hospital mortality, n (%)	0/66 (0.0%)	1/132 (0.8%)	n.e.	0/88 (0.0%)	1/88 (1.1%)	0.316
90-day mortality, n (%)	0/66 (0.0%)	2/132 (1.5%)	0.315	0/88 (0.0%)	1/88 (1.1%)	0.316
Close/involved margins (≤ 1 mm) for malignancies, n (%)	9/60 (15.0%)	21/121 (17.4%)	0.595	11/81 (13.6%)	15/83 (18.1%)	0.655

^aP-values were obtained from conditional logistic regression or mixed-effects quantile regression for binary and continuous variables, respectively. The respective marginal models were used when convergence could not be achieved. n.e., not evaluable. Bold represents statistically significant values.

The median operating time was significantly longer for the robotic group, with reduced median blood loss and lower proportion of patients with blood loss of > 500 ml. Open conversion was significantly lower in the robotic group (2.1 versus 9.4 per cent), with a lower rate of major morbidity (Clavien–Dindo grade > II). The remaining perioperative, intraoperative, and postoperative parameters were not significantly different between the groups. Oncological outcomes such as close/involved margins were similar between the groups (Table 2).

Comparison between R-RPS and L-RPS in matched cohorts

In the propensity-matched cohorts, the parameters of cirrhosis and ASA score were well matched in both the 1:1 and 2:1 cohorts (Table 3). Median blood loss, frequency of major blood loss (> 500 ml), need for intraoperative blood transfusion, and open conversion rate remained significantly lower with R-RPS, compared with L-RPS (Table 4). The median operating time and major morbidity rate did not differ significantly after PSM. There was no statistically significant difference in 30-day, 90-day, and inpatient mortality rates and the rate of close/involved margins.

Discussion

Previous studies have established the role of laparoscopic hepatectomy^{33–38}. Similar to conventional laparoscopy, RH has been reported to be associated with shorter hospital stay, lower cost, and fewer complications compared with open hepatectomy, albeit with longer operating times^{39,40}.

A recent updated meta-analysis found less blood loss and lower readmission rates but longer operating time for the robotic group. There were, however, no significant differences in the rates of overall complication, length of stay, conversion, and transfusion⁴¹. Similarly, an American College of Surgeons–National Surgical Quality Improvement Program (ACS–NSQIP) database review of 3152 MIH and 480 open surgery procedures were analysed. The robotic group comprising 240 patients showed longer operating times, but lower rates of open

conversion after 1:1 matching with the laparoscopic group. Significantly, laparoscopic resection with unplanned conversion was associated with increased morbidity. However, in this analysis, the proportion of major hepatectomy was only 13–14 per cent⁴².

A recent systematic review of robotic versus laparoscopic major hepatectomies involving 525 patients (300 laparoscopic versus 225 robotic) showed no significant differences regarding rates of overall complications, severe complications, and overall mortality. Perioperative parameters of blood loss, operating time, and length of stay, as well as conversion to open and transfusion rates, also were not significantly different⁴³. These results suggest that for more complex operations, the robotic platform was at least equivalent in outcomes to the laparoscopic approach.

The difficulty of resection in the posterosuperior segments in MIH has been well documented¹⁶. Many studies showed increased operating times, longer hospital stays, higher rates of conversions, and increased blood loss, compared with resections in the anterolateral segments for laparoscopy^{44,45}. Robotic assistance has been touted as a viable alternative without use of the thoracic–diaphragmatic approach or intercostal space approaches. The largest robotic series of 100 patients who underwent resection of lesions from the posterosuperior segments from a single centre showed nil conversions and 100 per cent R0 resection rate, with median blood losses of 100 ml and 50 ml for subsegmentectomy/segmentectomies and partial hepatectomies, respectively⁴⁶.

Anatomical RPS is generally considered challenging via laparoscopy, even for experienced laparoscopic HPB surgeons. The transection area is wider than for a formal right hepatectomy, and horizontal. Identification and isolation of the right posterior pedicle can be challenging, leading to a variable approach to its control for obtaining a demarcation line before parenchymal transection. The RHV does not always run in the intersectional plane, particularly in the inferior (caudal) area⁴⁷. Furthermore, the RHV usually has several thin-walled tributaries that are easily torn by the inexperienced surgeon, either by retraction or through injuries from inadequate cutting plane exposure,

injudicious use of energy device, or poor cavitron ultrasonic surgical aspirator (CUSA) technique. A detailed understanding of the preoperative anatomy of the inflow and RHV course, combined with a detailed study of the RHV, may go some way to mitigating the risk of potential catastrophic bleeding. Most laparoscopic surgeons would consider positioning the patient in the left lateral decubitus, reverse Trendelenburg position to elevate the cutting plane to a more vertical direction, while increasing drainage of the RHV down into the inferior vena cava (IVC)⁴⁸. Multiple techniques have been proposed with a vein-based approach, including the peripheral-to-root caudal approach and the root-to-peripheral approaches⁴⁹. This is coupled with a technique described as a back-scoring technique with CUSA to avoid split or pulled-up injuries of the hepatic vein, which may be employed to increase the success of this procedure⁵⁰. In the robotic technique, the positioning of the patient essentially mirrors that in the laparoscopic approach. Parenchymal transection is performed generally via either bipolar Maryland forceps or a harmonic scalpel clamp crush technique, or by use of harmonics by use of the harmonic scalpel with the jaws open, thus deploying the active jaw in a manner resembling the CUSA, which is not available for the robotic platform^{16,51}. In some centres, laparoscopic CUSA is used concurrently to overcome this limitation⁵².

In modern series, use of intravenous ICG as negative staining after pedicle control has been deployed in many expert centres to further guide precise anatomical resection both in laparoscopic surgery and in the robotic technique with Firefly⁵³. Despite all these technical advancements, a tumour measuring >3 cm requiring L-RPS is considered a surgical procedure reserved for the expert surgeon, according to the Iwate criteria. While some would consider performing a right hemihepatectomy as a simpler procedure, this goes against the principle of parenchymal preservation and increases the risk of morbidity and mortality associated with the operation. In addition, it may not be possible to safely perform a right hepatectomy due to lack of future liver remnant volume or limited ICG clearance (R15) in certain cases of cirrhosis and hepatocellular carcinoma. It is important to emphasize that if RPS is technically possible but not feasible via a minimally invasive approach, it is preferred for the surgeon to perform the appropriate procedure via the open approach, rather than by carrying out a bigger procedure such as right hepatectomy via the minimally invasive approach.

This study had limitations by including multiple centres with a different range of experience in both laparoscopic and robotic resections, each with their own approach and surgical technique. As with all retrospective analysis, there will inevitably be a potential for information bias and selection bias although attempts to mitigate this with propensity scoring in both 1:1 and 1:2 showed no significant difference in results. It is important to add that apparent advantages associated with R-RPS may not be attributable to the robotic platform. Confounding factors such as individual surgeon experience and selection bias likely could have accounted for some of the observations. Moreover, it is possible that surgeons adopted a more selective criteria when choosing to perform R-RPS due to the higher costs and need to satisfy the increase in patient expectations. The main advantages of R-RPS over L-RPS seem to be lower open conversion rates and reduced blood loss, and this should reduce morbidity risks^{54,55}.

Collaborators

M. D'Silva (Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine,

Seoul, Korea); H. Schotte (Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, Kortrijk, Belgium); C. De Meyere (Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, Kortrijk, Belgium); E. Lai (Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong SAR, China); F. Krenzien (Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin, and Berlin Institute of Health, Berlin, Germany); M. Schmelzle (Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin, Corporate Member of Freie Universität Berlin, and Berlin Institute of Health, Berlin, Germany); P. Kadam (Department of Hepatopancreatobiliary and Liver Transplant Surgery, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom); R. Montalti (Department of Clinical Medicine and Surgery, Division of HPB, Minimally Invasive and Robotic Surgery, Federico II University Hospital Naples, Naples, Italy); M. Giglio (Department of Clinical Medicine and Surgery, Division of HPB, Minimally Invasive and Robotic Surgery, Federico II University Hospital Naples, Naples, Italy); Q. Liu (Faculty of Hepatopancreatobiliary Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Beijing, China); K. F. Lee (Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, New Territories, Hong Kong SAR, China); D. Salimgereeva (Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Scientific Center, Moscow, Russia); R. Alikhanov (Department of Hepato-Pancreato-Biliary Surgery, Moscow Clinical Scientific Center, Moscow, Russia); L.-S. Lee (Hepatopancreatobiliary Unit, Department of Surgery, Changi General Hospital, Singapore); M. Gastaca (Hepatobiliary Surgery and Liver Transplantation Unit, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country, Bilbao, Spain); J. Y. Jang (Department of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea).

Disclosure: B.K.P.G. has received travel grants and honorarium from Johnson & Johnson and Transmedic, the local distributor for the Da Vinci Robot. M.V.M. is a consultant for CAVA Robotics LLC. J.P. has received a research grant from Intuitive Surgical Deutschland GmbH and personal fees or non-financial support from Johnson & Johnson, Medtronic, AFS Medical, Astellas, CHG Meridian, Chiesi, Falk Foundation, La Fource Group, Merck, Neovii, NOGGO, Pharma-Consult Peterson, and Promediceis. M. Schmelzle has received personal fees or other support outside of the submitted work from Merck, Bayer, ERBE, Amgen, Johnson & Johnson, Takeda, Olympus, Medtronic, and Intuitive.

The authors declare no other conflict of interest.

Supplementary material

Supplementary material is available at BJS online.

References

- Goh BKP, Lee S-Y, Teo J-Y, Kam J-H, Jeyaraj P-R, Cheow P-C et al. Changing trends and outcomes associated with the adoption of minimally invasive hepatectomy: a contemporary single-institution experience with 400 consecutive resections. *Surg Endosc* 2018;**32**:4658–4665. doi:10.1007/s00464-018-6310-1.

2. Magistri P, Assirati G, Ballarin R, Di Sandro S, Di Benedetto F. Major robotic hepatectomies: technical considerations. *Updates Surg* 2021;**73**:989–997. doi:10.1007/s13304-020-00940-1.
3. Choi GH, Chong JU, Han DH, Choi JS, Lee WJ. Robotic hepatectomy: the Korean experience and perspective. *Hepatobiliary Surg Nutr* 2017;**6**:230–238. doi:10.21037/hbsn.2017.01.14.
4. Ciria R, Cherqui D, Geller DA, Briceno J, Wakabayashi G. Comparative short-term benefits of laparoscopic liver resection: 9000 cases and climbing. *Ann Surg* 2016;**263**:761–777. doi:10.1097/SLA.0000000000001413.
5. Goh BKP, Syn N, Koh Y-X, Teo J-Y, Cheow P-C, Jeyaraj PR et al. Comparison between short and long-term outcomes after minimally invasive versus open primary liver resections for hepatocellular carcinoma: a 1:1 matched analysis. *J Surg Oncol* 2021;**124**:560–571. doi:10.1002/jso.26556.
6. Pan Y, Xia S, Cai J, Chen KN, Cai X. Efficacy of laparoscopic hepatectomy versus open surgery for hepatocellular carcinoma with cirrhosis: a meta-analysis of case-matched studies. *Front Oncol* 2021;**11**:652272. doi:10.3389/fonc.2021.652272.
7. Hildebrand N, Verkoulen K, Dewulf M, Heise D, Ulmer F, Coolsen M et al. Short-term outcomes of laparoscopic versus open hepatectomy in the elderly patient: systematic review and meta-analysis. *HPB (Oxford)* 2021;**23**:984–980. doi:10.1016/j.hpb.2021.01.016.
8. Buell JF, Cherqui D, Geller DA, O'Rourke N, Iannitti D, Dagher I et al.; World Consensus Conference on Laparoscopic Surgery. The international position on laparoscopic liver surgery: The Louisville Statement, 2008. *Ann Surg* 2009;**250**:825–830.
9. Wakabayashi G, Cherqui D, Geller DA, Buell JF, Kaneko H, Han HS et al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. *Ann Surg* 2015;**261**:619–629.
10. Cheung TT, Han H-S, She WH, Chen K-H, Chow PKH, Yoong BK et al. The Asia Pacific Consensus statement on laparoscopic liver resection for hepatocellular carcinoma: a report from the 7th Asia-Pacific primary liver cancer expert meeting held in Hong Kong. *Liver Cancer* 2018;**7**:28–39.
11. Abu Hilal M, Aldrighetti L, Dagher I, Edwin B, Troisi RI, Alikhanov R et al. The Southampton Consensus Guidelines for laparoscopic liver surgery: from indication to implementation. *Ann Surg* 2018;**268**:11–18.
12. Ciria R, Berardi G, Nishino H, Chan ACY, Chanwat R, Chen KH et al.; Study group of Precision Anatomy for Minimally Invasive Hepato-Biliary-Pancreatic surgery (PAM-HBP surgery). A snapshot of the 2020 conception of anatomic liver resections and their applicability on minimally invasive liver surgery. A preparatory survey for the Expert Consensus Meeting on Precision Anatomy for Minimally Invasive HBP Surgery. *J Hepatobiliary Pancreat Sci* 2021. DOI: 10.1002/jhbp.959.
13. Goh BKP, Lee S-Y, Koh Y-X, Kam J-H, Chan C-Y. Minimally invasive major hepatectomies: a Southeast Asian single institution contemporary experience with its first 120 consecutive cases. *ANZ J Surg* 2020;**90**:553–557. doi:10.1111/ans.15563.
14. Sucandy I, Luberic K, Lippert T, Castro M, Krill E, Ross S et al. Robotic major hepatectomy: an institutional experience and clinical outcomes. *Ann Surg Oncol* 2020;**27**:4970–4979. doi:10.1245/s10434-020-08845-4.
15. Choi SH, Han DH, Lee JH, Choi YR, Lee JH, Choi GH et al. Safety and feasibility of robotic major hepatectomy for novice surgeons in robotic liver surgery: a prospective multicenter pilot study. *Surg Oncol* 2020;**35**:39–46. doi:10.1016/j.sur-onc.2020.07.003.
16. Gholami S, Judge SJ, Lee S-Y, Mashayekhi K, Goh BKP, Chan C-Y et al. Is minimally invasive surgery of lesions in the right superior segments of the liver justified? A multi-institutional study of 245 patients. *J Surg Oncol* 2020;**122**:1428–1434. doi:10.1002/jso.26154. Epub 2020 Aug 16. PMID: 33459363; PMCID: PMC7978501.
17. Wakabayashi G. What has changed after the Morioka consensus conference, 2014 on laparoscopic liver resection? *Hepatobiliary Surg Nutr* 2016;**5**:281–289.
18. Kawaguchi Y, Fuks D, Kokudo N, Gayet B. Difficulty of laparoscopic liver resection: proposal for a new classification. *Ann Surg* 2018;**267**:13–17.
19. Luo D, Xiong X, Xiong H, Liu H, Huang Y, Huang M et al. The safety and feasibility of laparoscopic technology in right posterior sectionectomy. *Surg Laparosc Endosc Percutan Tech* 2020;**30**:169–172. doi:10.1097/SLE.0000000000000772.
20. Homma Y, Honda G, Kurata M, Ome Y, Doi M, Yamamoto J. Pure laparoscopic right posterior sectionectomy using the caudate lobe-first approach. *Surg Endosc* 2019;**33**:3851–3857. doi:10.1007/s00464-019-06877-w.
21. D'Hondt M, Ovaere S, Knol J, Vandeputte M, Parmentier I, De Meyere C et al. Laparoscopic right posterior sectionectomy: single-center experience and technical aspects. *Langenbecks Arch Surg* 2019;**404**:21–29. doi:10.1007/s00423-018-1731-9.
22. Siddiqi NN, Abuawwad M, Halls M, Rawashdeh A, Giovinazzo F, Aljaioussi A et al. Laparoscopic right posterior sectionectomy (LRPS): surgical techniques and clinical outcomes. *Surg Endosc* 2018;**32**:2525–2532. doi:10.1007/s00464-017-5958-2.
23. Goh BKP, Lee L-S, Lee S-Y, Chow PKH, Chan C-Y, Chioi AKH et al. Initial experience with robotic hepatectomy in Singapore: analysis of 48 resections in 43 consecutive patients. *ANZ J Surg* 2019;**89**:201–205. doi:10.1111/ans.14417.
24. Aziz H, Wang JC, Genyk Y, Sheikh MR. Comprehensive analysis of laparoscopic, robotic, and open hepatectomy outcomes using the nationwide readmissions database. *J Robot Surg* 2021. DOI: 10.1007/s11701-021-01257-w.
25. Miller HP, Hakim A, Kellish A, Wozniak M, Gaughan J, Sensenig R et al. Cost-benefit analysis of robotic vs. laparoscopic hepatectomy: a propensity-matched retrospective cohort study of American College of Surgeons National Surgical Quality Improvement Program Database. *Am Surg* 2021;in press.
26. Wong DJ, Wong MJ, Choi GH, Wu YM, Lai PB, Goh BKP et al. Systematic review and meta-analysis of robotic versus open hepatectomy. *ANZ J Surg* 2019;**89**:165–170. doi:10.1111/ans.14690.
27. Wang J-M, Li J-F, Yuan G-D, He S-Q. Robot-assisted versus laparoscopic minor hepatectomy: a systematic review and meta-analysis. *Medicine (Baltimore)* 2021;**100**:e25648. doi:10.1097/MD.00000000000025648.
28. Pang YY. The Brisbane 2000 terminology of liver anatomy and resections. *HPB (Oxford)* 2002;**4**:99; author reply 99–100.
29. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;**240**:205–213.
30. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H et al. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. *Eur Heart J* 2012;**33**:1893–1901.
31. Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. *Stat Med* 2014;**33**:1242–1258.

32. Glauser G, Osiemo B, Goodrich S, McClintock SD, Vollmer C, DeMatteo R et al. Association of overlapping, nonconcurrent, surgery with patient outcomes at a large academic medical center: a coarsened exact matching study. *Ann Surg* 2019;**270**:620–629.
33. Macacari RL, Coelho FF, Bernardo WM, Kruger JAP, Jeismann VB, Fonseca GM et al. Laparoscopic vs. open left lateral sectionectomy: an update meta-analysis of randomized and non-randomized controlled trials. *Int J Surg* 2019;**61**:1–10. doi: 10.1016/j.ijsu.2018.11.021.
34. Witowski J, Rubinkiewicz M, Mizera M, Wysocki M, Gajewska N, Sitkowski M et al. Meta-analysis of short- and long-term outcomes after pure laparoscopic versus open liver surgery in hepatocellular carcinoma patients. *Surg Endosc* 2019;**33**:1491–1507. doi:10.1007/s00464-018-6431-6.
35. Goh EL, Chidambaram S, Ma S. Laparoscopic vs open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a meta-analysis of the long-term survival outcomes. *Int J Surg* 2018;**50**:35–42. doi:10.1016/j.ijsu.2017.12.021.
36. Xie S-M, Xiong J-J, Liu X-T, Chen H-Y, Iglesia-García D, Altaf K et al. Erratum to: Laparoscopic versus open liver resection for colorectal liver metastases: a comprehensive systematic review and meta-analysis. *Sci Rep* 2017;**7**:1012. doi: 10.1038/s41598-017-00978-z.
37. Robles-Campos R, Lopez-Lopez V, Brusadin R, Lopez-Conesa A, Gil-Vazquez PJ, Navarro-Barrios Á et al. Open versus minimally invasive liver surgery for colorectal liver metastases (LapOpHuva): a prospective randomized controlled trial. *Surg Endosc* 2019;**33**:3926–3936. doi:10.1007/s00464-019-06679-0.
38. Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, Kazaryan AM, Kristiansen R, Fagerland MW et al. Laparoscopic versus open resection for colorectal liver metastases: The OSLO-COMET randomized controlled trial. *Ann Surg* 2018;**267**:199–207. doi: 10.1097/SLA.0000000000002353.
39. Machairas N, Papaconstantinou D, Tsilimigras DI, Moris D, Prodromidou A, Paspala A et al. Comparison between robotic and open liver resection: a systematic review and meta-analysis of short-term outcomes. *Updates Surg* 2019;**71**:39–48. doi: 10.1007/s13304-019-00629-0.
40. Montalti R, Berardi G, Patrì A, Vivarelli M, Troisi RI et al. Outcomes of robotic vs laparoscopic hepatectomy: a systematic review and meta-analysis. *World J Gastroenterol* 2015;**21**: 8441–8451. doi:10.3748/wjg.v21.i27.8441.
41. Kamarajah SK, Bundred J, Manas D, Jiao LR, Hilal MA, White SA et al. Robotic versus conventional laparoscopic liver resections: a systematic review and meta-analysis. *Scand J Surg* 2020; 1457496920925637. doi: 10.1177/1457496920925637.
42. Fagenson AM, Gleeson EM, Pitt HA, Lau KN. Minimally invasive hepatectomy in North America: laparoscopic versus robotic. *J Gastrointest Surg* 2021;**25**:85–93. doi:10.1007/s11605-020-04703-6.
43. Ziogas IA, Giannis D, Esagian SM, Economopoulos KP, Tohme S, Geller DA et al. Laparoscopic versus robotic major hepatectomy: a systematic review and meta-analysis. *Surg Endosc* 2021;**35**: 524–535. doi:10.1007/s00464-020-08008-2.
44. Lee W, Han H-S, Yoon Y-S, Cho JY, Choi YR, Shin HK et al. Comparison of laparoscopic liver resection for hepatocellular carcinoma located in the posterosuperior segments or anterolateral segments: a case-matched analysis. *Surgery* 2016;**160**: 1219–1226. doi:10.1016/j.surg.2016.05.009.
45. Teo JY, Kam JH, Chan CY, Goh BK, Wong JS, Lee VT et al. Laparoscopic liver resection for posterosuperior and anterolateral lesions—a comparison experience in an Asian centre. *Hepatobiliary Surg Nutr* 2015;**4**:379–390. doi:10.3978/j.issn.2304-3881.2015.06.06.
46. Zhao Z, Yin Z, Pan L, Li C, Hu M, Lau WY et al. Robotic hepatic resection in postero-superior region of liver. *Updates Surg* 2021;**73**: 1007–1014. doi:10.1007/s13304-020-00895-3.
47. Sato F, Igami T, Ebata T, Yokoyama Y, Sugawara G, Mizuno T et al. A study of the right intersectional plane (right portal scissura) of the liver based on virtual left hepatic trisectionectomy. *World J Surg* 2014;**38**:3181–3185. doi: 10.1007/s00268-014-2718-5.
48. Thiruchelvam N, Lee SY, Chiow AKH. Patient and port positioning in laparoscopic liver resections. *Hepatoma Res* 2021;**7**:22. doi: 10.20517/2394-5079.2020.144.
49. Monden K, Alconchel F, Berardi G, Ciria R, Akahoshi K, Miyasaka Y et al.; Study Group of Precision Anatomy for Minimally Invasive Hepato-Biliary-Pancreatic surgery (PAM-HBP surgery). Landmarks and techniques to perform minimally invasive liver surgery: a systematic review with a focus on hepatic outflow. *J Hepatobiliary Pancreat Sci* 2021. DOI: 10.1002/jhbp.898.
50. Honda G, Ome Y, Yoshida N, Kawamoto Y. How to dissect the liver parenchyma: excavation with cavitron ultrasonic surgical aspirator. *J Hepatobiliary Pancreat Sci* 2020;**27**:907–912. doi: 10.1002/jhbp.829.
51. Wu Y-M, Hu R-H, Lai H-S, Lee P-H. Robotic-assisted minimally invasive liver resection. *Asian J Surg* 2014;**37**:53–57. doi: 10.1016/j.asjsur.2014.01.015.
52. Hawksworth J, Llore N, Holzner ML, Radkani P, Meslar E, Winslow E et al. Robotic hepatectomy is a safe and cost-effective alternative to conventional open hepatectomy: a single-center preliminary experience. *J Gastrointest Surg* 2021; **25**:825–828.
53. Chiow AKH, Rho SY, Wee IJY, Lee LS, Choi GH. Robotic ICG guided anatomical liver resection in a multi-centre cohort: an evolution from “positive staining” into “negative staining” method. *HPB (Oxford)* 2021;**23**:475–482. doi:10.1016/j.hpb.2020.08.005.
54. van der Heijde N, Ratti F, Aldrighetti L, Benedetti Cacciaguerra A, Can MF, D’Hondt M et al. Laparoscopic versus open right posterior sectionectomy: an international, multicenter, propensity score-matched evaluation. *Surg Endosc* 2020. DOI: 10.1007/s00464-020-08109-y.
55. Halls MC, Cipriani F, Berardi G, Barkhatov L, Lainas P, Alzoubi M et al. Conversion for unfavorable intraoperative events results in significantly worse outcomes during laparoscopic liver resection: lessons learned from a multicenter review of 2861 cases. *Ann Surg* 2018;**268**:1051–1057. doi:10.1097/SLA.0000000000002332.